Stinginn LLC develops therapeutics that use the immune system to combat infectious disease, inflammation, and cancer. STING is a cellular protein that regulates the production of cytokines to fight microbial infection and generate anti-tumor immunity. The firm's solutions include a variety of immunotherapeutic strategies that help control and regulate STING signaling pathway. The immunotherapies have applications for both anti-tumor, anti-inflammatory, and anti-microbial solutions. The company has developed multiple compounds such as Nucleic acid-based STING activators, novel assays, oncolytic viruses, and other treatment solutions.
